Molho P, Rolland N, Lebrun T, Dirat G, Courpied J P, Croughs T, Duprat I, Sultan Y
Cochin Hospital Group, Paris, France.
Haemophilia. 2000 Jan;6(1):23-32. doi: 10.1046/j.1365-2516.2000.00358.x.
One hundred and 16 patients contributed to an analysis of the impact of the consequences of severe haemophilia A or B (factor levels < 2%) on orthopaedic status, resources consumed in relation to this status and resultant cost, and quality of life as perceived by the patient, using the MOS 36-Item-Short-Form Health Survey (SF-36). This French cross-sectional study involved outpatients regularly attending a haemophilia treatment centre. Data were collected retrospectively over a period of 1 year by the physician of the haemophilia treatment centre. Patients had a mean age of 23, and consisted of 50% students, 25% salaried workers, 17.2% with no professional activity and 7.8% physically impaired; 82.8% of them had type A haemophilia. Mean pain score was 2.5 per patient for the six main joints; 7.7 for the clinical score and 18.8 for the radiological score, with a mean number of bleeds of 16.3 per year per patient. During the year prior to inclusion, and because of their orthopaedic status, 22.4% of patients were hospitalized, 76.7% attended for an outpatient visit and 76.7% required at least one special investigation; 97.4% received replacement therapy, 41.4% required treatment for joint pain and 42.2% orthopaedic equipment. The less affected dimensions were the physical function (76.8 +/- 22. 2) and the social relations (76.1 +/- 23.1). Least good quality of life scores concerned the pain (60.2 +/- 25.2), perception of general health (59.3 +/- 23.1) and vitality (57.8 +/- 19.5) dimensions. The age was a discriminant criterion since quality of life was better in patients of the 18-23 age group for five dimensions. Mean annual treatment costs of a patient with severe haemophilia were determined as 425 762 French francs ($73 029). Loss of production was estimated at a mean of 4609 French francs ($791) per active patient over the course of the year. Results showed indirect evidence of the usefulness of early home treatment.
116名患者参与了一项分析,该分析旨在研究重度A型或B型血友病(因子水平<2%)的后果对骨科状况、与此状况相关的资源消耗及由此产生的成本,以及患者所感知的生活质量的影响,采用医学结局研究简明健康调查量表(SF - 36)。这项法国横断面研究纳入了定期前往血友病治疗中心就诊的门诊患者。血友病治疗中心的医生在1年时间里回顾性收集了数据。患者的平均年龄为23岁,其中50%是学生,25%是受薪工人,17.2%无职业活动,7.8%身体有残疾;82.8%的患者为A型血友病。每位患者六个主要关节的平均疼痛评分为2.5;临床评分为7.7,放射学评分为18.8,每位患者每年的平均出血次数为16.3次。在纳入研究前的一年中,由于骨科状况,22.4%的患者住院治疗,76.7%的患者门诊就诊,76.7%的患者至少需要一项特殊检查;97.4%的患者接受替代治疗,41.4%的患者需要治疗关节疼痛,42.2%的患者需要骨科设备。受影响较小的维度是身体功能(76.8±22.2)和社会关系(76.1±23.1)。生活质量得分最低的是疼痛(60.2±25.2)、总体健康感知(59.3±23.1)和活力(57.8±19.5)维度。年龄是一个判别标准,因为18 - 23岁年龄组的患者在五个维度上的生活质量更好。重度血友病患者的平均年治疗成本确定为425762法国法郎(73029美元)。每位在职患者一年的生产损失估计平均为4609法国法郎(791美元)。结果显示了早期家庭治疗有效性的间接证据。